Recent

% | $
Quotes you view appear here for quick access.

Delcath Systems, Inc. Message Board

  • haresh700707 haresh700707 Feb 11, 2013 11:53 AM Flag

    My Research on DCTH

    I was digging deeper into the history of this company and came across a few good article:

    1. Feb 22, 2011 - Adam Feuerstien
    Delcath drop 28% to $8.00 ...FDA issue "refuse to file" letter.... FDA requested information involving manufacturing plant inspection timing, product & sterilization valitation, and additional safety information.
    Note: more information about Phase III was not requested

    2. Oct 10, 2012 - Mark Messier - On 8-15-2012 Decalth requested priority review

    3. Oct 15, 2012 - Scott Donnelly - FDA accept Delcath application -- Delcath recieve a standard review apploval ...revenue could be as high as $2 Billion.......Phase 2 trial for patients with unresectable liver cancer ---- data show 70% of 20 patients showed a hepatic response after 3 treatments, whereas normalized response rate for these patients under current treatment arm would be 5%.

    I am still researching this company. Given the potential for $2B revenue and great phase II result, why is DCTH still trading at $1.5. At this point in time it should be around $10.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • tcracker09@ymail.com tcracker09 Feb 11, 2013 1:31 PM Flag

      $2B is a long ways off, initially, they will be in a 500 million market once FDA approval is given. Revenues in a 500 million market, once insurers reimburse, can put DCTH at a market cap double what it is now. It's going to take years. This stock could easily go to $10, and back down to $2.00 afterwards. GL

      Sentiment: Hold

 
DCTH
0.43-0.01(-1.80%)Sep 1 3:25 PMEDT